Sign In
Buy OKYO
$1.66
-0.0400 (-2.35%)
At Close: Jun 03, 2026
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
07:00am, Thursday, 19'th Mar 2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
Alibaba Group reports revenue miss for December quarter, shares fall
06:08am, Thursday, 19'th Mar 2026
Alibaba Group (NYSE:BABA) reported weaker-than-expected results for its December quarter, as revenue fell short of forecasts and profits declined sharply,...
FTSE 100 Live: Stocks expected to slump as oil prices soar on Iran counterattacks
03:07am, Thursday, 19'th Mar 2026
7.16am: FTSE 100 called over 100 points lower as oil soars The FTSE 100 is expected to nosedive more than 100 points on Thursday morning as oil prices...
The Trade Desk under pressure after audit allegations, Jefferies flags growth risks
11:47am, Wednesday, 18'th Mar 2026
Jefferies analysts have struck a cautious tone on The Trade Desk (NASDAQ:TTD), warning that recent developments involving one of its largest agency partners...
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
09:03am, Wednesday, 18'th Mar 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said on Wednesday it observed improvements in quality-of-life measures in patients treated with its experimental therapy urcosimod in a mid-stage study for neuropathic co
LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
05:02am, Wednesday, 18'th Mar 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said on Wednesday it observed improvements in quality-of-life measures in patients treated with its experimental therapy...
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of “Hold” from Analysts
02:24am, Tuesday, 17'th Mar 2026
Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ: OKYO - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the firm, Marketbeat.com reports. One a
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
12:01pm, Monday, 23'rd Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been ac
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
11:56am, Monday, 23'rd Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye...
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
11:00am, Monday, 23'rd Feb 2026
LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
12:59pm, Tuesday, 17'th Feb 2026
Analysts from Lucid Capital, H.C. Wainwright, and B.
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
07:56am, Tuesday, 17'th Feb 2026
Analysts from Lucid Capital, H.C. Wainwright, and B. Riley Securities have all repeated ‘Buy’ ratings on OKYO Pharma Ltd (NASDAQ:OKYO), highlighting the...
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
09:11am, Friday, 13'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds of about $20 million. The clinical-stage bi
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
03:50am, Friday, 13'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds...
